Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Arance

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Expert Opinion on Pharmacotherapy|May 31, 2002
Assessing outcomes in palliative chemotherapyEmma Cattell, Ana Arance, Mark Middleton
Cells|September 28, 2021
Molecular Markers and Targets in MelanomaCristina Teixido, Paola Castillo, Clara Martinez-Vila, et al.
Immunotherapy|April 28, 2021
Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communicationFrancisco Aya, E Azucena González-Navarro, Clara Martínez, et al.
Future Oncology (London, England)|September 2, 2016
Ipilimumab after progression on anti-PD-1 treatment in advanced melanomaFrancisco Aya, Lydia Gaba, Iván Victoria, et al.
Immunotherapy|April 27, 2016
Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumabFrancisco Aya, Aranzazu Fernández-Martínez, Lydia Gaba, et al.
International Journal of Molecular Sciences|September 14, 2024
Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist's Perspective on Current KnowledgeClara Martínez-Vila, Europa Azucena González-Navarro, Cristina Teixido, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patientsPaola Castillo, Marta Marginet, Pedro Jares, et al.
Cell Reports|April 13, 2024
Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanomaFrancisco Aya, Pablo Lanuza-Gracia, Abel González-Pérez, et al.
International Journal of Molecular Sciences|January 25, 2025
Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in MelanomaClara Martínez-Vila, Cristina Teixido, Francisco Aya, et al.
Acta Dermato-Venereologica|May 18, 2021
Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease RecurrenceSümeyre Seda Ertekin, Sebastian Podlipnik, Constanza Riquelme-Mc Loughlin, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Expert Opinion on Pharmacotherapy|May 31, 2002
Assessing outcomes in palliative chemotherapyEmma Cattell, Ana Arance, Mark Middleton
Cells|September 28, 2021
Molecular Markers and Targets in MelanomaCristina Teixido, Paola Castillo, Clara Martinez-Vila, et al.
Immunotherapy|April 28, 2021
Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communicationFrancisco Aya, E Azucena González-Navarro, Clara Martínez, et al.
Future Oncology (London, England)|September 2, 2016
Ipilimumab after progression on anti-PD-1 treatment in advanced melanomaFrancisco Aya, Lydia Gaba, Iván Victoria, et al.
Immunotherapy|April 27, 2016
Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumabFrancisco Aya, Aranzazu Fernández-Martínez, Lydia Gaba, et al.
International Journal of Molecular Sciences|September 14, 2024
Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist's Perspective on Current KnowledgeClara Martínez-Vila, Europa Azucena González-Navarro, Cristina Teixido, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patientsPaola Castillo, Marta Marginet, Pedro Jares, et al.
Cell Reports|April 13, 2024
Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanomaFrancisco Aya, Pablo Lanuza-Gracia, Abel González-Pérez, et al.
International Journal of Molecular Sciences|January 25, 2025
Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in MelanomaClara Martínez-Vila, Cristina Teixido, Francisco Aya, et al.
Acta Dermato-Venereologica|May 18, 2021
Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease RecurrenceSümeyre Seda Ertekin, Sebastian Podlipnik, Constanza Riquelme-Mc Loughlin, et al.
Pageof 10